SC
AVEO

Sculptor Capital’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Sculptor Capital’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-36,280
Closed -$244K – 340
2019
Q2 		$244K Hold
36,280
– – ﹤0.01% 257
2019
Q1 		$298K Hold
36,280
– – ﹤0.01% 198
2018
Q4 		$580K Buy
+36,280
New +$798K ﹤0.01% 175

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Sculptor Capital's AVEO Position: Q3 2019 in Review

Sculptor Capital sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2019, closing a stake of 36,280 shares — an estimated $244K sold.

Sculptor Capital first reported a position in AVEO in Q4 2018 and held it in 3 quarters. The position peaked at $580K in Q4 2018. 59 funds tracked by Wall St. Rank hold AVEO as of Q3 2019.

  • Sculptor Capital reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Sculptor Capital sold 36,280 AVEO Pharmaceuticals, Inc. shares in Q3 2019, an estimated $244K.
  • Sculptor Capital first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
  • Sculptor Capital's AVEO Pharmaceuticals, Inc. position peaked at $580K in Q4 2018.
  • 59 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2019.

Based on Sculptor Capital's 13F filing for Q3 2019, filed 14 Nov 2019.